Kedrion Biopharma

Kedrion Biopharma collects and fractionates blood plasma to produce and distribute plasma‑derived therapies for rare, ultra‑rare, and debilitating conditions, including coagulation and neurological disorders, immunodeficiencies, and Rh sensitization. 

We employ approximately 5,400 people worldwide and operate plasma collection centers in the United States and the Czech Republic. 


With a portfolio of 39 products distributed in over 100 countries, Kedrion is the world’s fifth‑largest player in plasma‑derived products.

We are committed to creating a world where science and care know no bounds.